Abstract
The combination of radiation and chemotherapy, based on a demonstrated preclinical rationale, has involved in the last decades the use of cytotoxic agents as radiosensitizers. Classic chemotherapeutic agents, such as 5-fluouracil and cisplatin, and more recently gemcitabine and taxanes, have been employed in different sequences with radiation therapy, even though the optimal combinations and scheduling are still in evolution. During recent years, due to the highly improved molecular understanding of intrinsic radioresistance and the profiling of cellular response to irradiation, a big effort exists in basic and translational research to identify novel treatment modalities combining radiation therapy with molecules that target very specific molecular pathways.
Keywords: Radiochemotherapy biological rationale, radiation sensitizers, 5-Fluouracil, Platinum, gemcitabine, taxol, epidermal growth factor inhibitors, epigenetic gene expression modulators
Current Drug Therapy
Title: The Association of Chemotherapy and Radiotherapy: Biological Rationale
Volume: 5 Issue: 3
Author(s): Donatella Tirindelli Danesi
Affiliation:
Keywords: Radiochemotherapy biological rationale, radiation sensitizers, 5-Fluouracil, Platinum, gemcitabine, taxol, epidermal growth factor inhibitors, epigenetic gene expression modulators
Abstract: The combination of radiation and chemotherapy, based on a demonstrated preclinical rationale, has involved in the last decades the use of cytotoxic agents as radiosensitizers. Classic chemotherapeutic agents, such as 5-fluouracil and cisplatin, and more recently gemcitabine and taxanes, have been employed in different sequences with radiation therapy, even though the optimal combinations and scheduling are still in evolution. During recent years, due to the highly improved molecular understanding of intrinsic radioresistance and the profiling of cellular response to irradiation, a big effort exists in basic and translational research to identify novel treatment modalities combining radiation therapy with molecules that target very specific molecular pathways.
Export Options
About this article
Cite this article as:
Tirindelli Danesi Donatella, The Association of Chemotherapy and Radiotherapy: Biological Rationale, Current Drug Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157488510791561101
DOI https://dx.doi.org/10.2174/157488510791561101 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, Pharmacological Properties and Analysis
Current Pharmaceutical Analysis Phytotherapeutic Agents for Benign Prostatic Hyperplasia: An Overview
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Current Protein & Peptide Science Formulation, Characterisation and In vitro Cytotoxic Effect of Lens culinaris Medikus Seeds Extract Loaded Chitosan Microspheres
Current Molecular Pharmacology Laminin and Collagen IV: Two Polypeptides as Marker of Dystocic Labor
Current Protein & Peptide Science Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Pharmacogenomics of 5-Fluorouracil/Oxaliplatin in Colorectal Cancer
Current Pharmacogenomics Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging
Current Topics in Medicinal Chemistry Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Natural Compounds in Anti-Leukaemic Therapy: A Review
Mini-Reviews in Medicinal Chemistry Flavonoids as Anticancer Agents: Recent Progress and State of the Art?
Current Organic Chemistry Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mini-Reviews in Medicinal Chemistry Pharmacogenetics, Regulation and Structural Properties of the Drugmetabolizing Enzymes Arylamine N-acetyltransferases
Current Pharmacogenomics Surgical Treatment in FIGO Stage I Cervical Cancer: Evolution of Concepts
Current Women`s Health Reviews Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics